Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | SLC5A2 | P31639 | 7/20 | 0.53 |
| ▸ | SLC5A1 | P13866 | 4/20 | 0.51 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TYR | P14679 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17439159 | 1.00 | ATM (0.56) | ATMEPHX2SLC5A2SLC5A1SLC28A3 | |
| SCHEMBL19846979 | 1.00 | ATM (0.56) | ATMEPHX2SLC5A2SLC5A1SLC28A3 | |
| SCHEMBL6561299 | 1.00 | ATM (0.56) | ATMEPHX2SLC5A2SLC5A1SLC28A3 | |
| SCHEMBL19854889 | 1.00 | ATM (0.56) | ATMEPHX2SLC5A2SLC5A1SLC28A3 | |
| SCHEMBL29461029 | 1.00 | ATM (0.56) | ATMEPHX2SLC5A2SLC5A1SLC28A3 | |
| SCHEMBL3191173 | 1.00 | ATM (0.56) | ATMEPHX2SLC5A2SLC5A1SLC28A3 | |
| SCHEMBL3648218 | 0.85 | SLC5A2 (0.42) | ATMEPHX2SLC5A2SLC5A1SLC28A3 | |
| SCHEMBL22412720 | 0.85 | SLC5A2 (0.42) | ATMEPHX2SLC5A2SLC5A1SLC28A3 | |
| SCHEMBL19846978 | 0.83 | SLC28A3 (0.54) | ATMEPHX2SLC5A2SLC5A1SLC28A3 | |
| SCHEMBL8516031 | 0.83 | KMT2A (0.51) | ATMEPHX2SLC5A2SLC5A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2596119-A2 | METHODS FOR DETECTION OF RARE SUBPOPULATIONS OF CELLS AND HIGHLY PURIFIED COMPOSITIONS OF CELLS | Advanced Cell Technology, Inc. (US) | 2013-05-29 | — | — | EP | claimed |
| WO-2012012803-A2 | METHODS FOR DETECTION OF RARE SUBPOPULATIONS OF CELLS AND HIGHLY PURIFIED COMPOSITIONS OF CELLS | ADVANCED CELL TECHNOLOGY, INC. (US) | 2012-01-26 | — | — | WO | claimed |
| US-20090068696-A1 | COMPOSITIONS AND MEANS FOR DIAGNOSING MICROBIAL INFECTIONS | STATENS SERUM INSTITUT | 2009-03-12 | — | — | US | claimed |
| US-20240212150-A1 | MATERIALS AND METHODS RELATED TO IMAGE PROCESSING | ADVANCED CELL DIAGNOSTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240209423-A1 | METHODS AND COMPOSITIONS FOR REDUCING AUTOFLUORESCENCE | ADVANCED CELL DIAGNOSTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| EP-4376887-A2 | MATERIALS AND METHODS OF MAKING OR USING IL-23R BINDING PROTEINS | Janssen Biotech, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2024026253-A1 | METHODS FOR TREATING PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND 191P4D12 PROTEINS IN COMBINATION WITH PEMBROLIZUMAB | AGENSYS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20240026419-A1 | METHODS FOR DETECTION OF RARE SUBPOPULATIONS OF CELLS AND HIGHLY PURIFIED COMPOSITION OF CELLS | ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE (US) | 2024-01-25 | — | — | US | disclosed |
| US-20230364254-A1 | METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230330251-A1 | METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11788124-B2 | Methods to further enhance signal amplification for the in situ detection of nucleic acids | ADVANCED CELL DIAGNOSTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| EP-0897428-B2 | TEST MEDIA AND QUANTITATIVE METHOD FOR IDENTIFICATION AND DIFFERENTIATION OF BIOLOGICAL MATERIALS IN A TEST SAMPLE | RCR SCIENT INC (US) | 2011-07-13 | — | — | EP | disclosed |
| EP-2181330-A1 | COMPOSITIONS AND MEANS FOR DIAGNOSING MICROBIAL INFECTIONS | Statens Serum Institut (DK) | 2010-05-05 | — | — | EP | disclosed |
| US-20090068696-A1 | COMPOSITIONS AND MEANS FOR DIAGNOSING MICROBIAL INFECTIONS | STATENS SERUM INSTITUT | 2009-03-12 | — | — | US | disclosed |
| WO-2009026920-A1 | COMPOSITIONS AND MEANS FOR DIAGNOSING MICROBIAL INFECTIONS | STATENS SERUM INSTITUT (DK) | 2009-03-05 | — | — | WO | disclosed |
| EP-0897428-B1 | TEST MEDIA AND QUANTITATIVE METHOD FOR IDENTIFICATION AND DIFFERENTIATION OF BIOLOGICAL MATERIALS IN A TEST SAMPLE | RCR SCIENT INC (US) | 2007-06-06 | — | — | EP | disclosed |
| EP-0897428-A4 | TEST MEDIA AND QUANTITATIVE METHOD FOR IDENTIFICATION AND DIFFERENTIATION OF BIOLOGICAL MATERIALS IN A TEST SAMPLE | RCR SCIENT INC (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-0897428-A1 | TEST MEDIA AND QUANTITATIVE METHOD FOR IDENTIFICATION AND DIFFERENTIATION OF BIOLOGICAL MATERIALS IN A TEST SAMPLE | RCR Scientific, Inc. (US) | 1999-02-24 | — | — | EP | disclosed |
| US-5726031-A | Test media and quantitative method for identification and differentiation of biological materials in a test sample | RCR SCIENTIFIC, INC. (US) | 1998-03-10 | — | — | US | disclosed |
| WO-1997036001-A1 | TEST MEDIA AND QUANTITATIVE METHOD FOR IDENTIFICATION AND DIFFERENTIATION OF BIOLOGICAL MATERIALS IN A TEST SAMPLE | RCR SCIENTIFIC, INC. (US) | 1997-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330251-A1 | METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | CD2BP2, IGSF11, DNAH12 | ATM 4106/4885EPHX2 3552/4885SLC5A2 3872/4885 |
| US-20230364254-A1 | METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | NECTIN4, CD2BP2, CD22 | ATM 4466/4885EPHX2 4133/4885SLC5A2 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.